Core definitions revisited

🟢 Lite — Quick Review (1h–1d)

Rapid summary for last-minute revision before your exam.

Selective toxicity is the guiding principle: an antimicrobial must harm the pathogen without damaging the host. Minimum Inhibitory Concentration (MIC) is the lowest drug concentration that visibly suppresses bacterial growth in vitro after 16–20 hours of standardized incubation (~5×10⁵ CFU/mL inoculum at 35–37 °C). Minimum Bactericidal Concentration (MBC) is the concentration that kills ≥99.9% of the inoculum (≥3 log₁₀ drop) on subculture to drug-free agar. For most bactericidal agents, MBC ≈ 2–4 × MIC.

Key classification anchor: β-lactams and glycopeptides target cell-wall synthesis; macrolides, tetracyclines, aminoglycosides, chloramphenicol, clindamycin, linezolid target the ribosome; fluoroquinolones block DNA gyrase/topoisomerase IV; rifampicin inhibits RNA polymerase; sulfonamides + trimethoprim block folate synthesis; daptomycin and polymyxins disrupt membranes.

PK/PD class	Optimized index	Example drugs
Time-dependent	%T > MIC	β-lactams, vancomycin
Concentration-dependent	Cmax/MIC and AUC₂₄h/MIC	Aminoglycosides, fluoroquinolones

Exam tip: A question stem giving an MIC value followed by an outcome almost always tests the definition, not a calculation.

🟡 Standard — Regular Study (2d–2mo)

Standard content for students with a few days to months.

Core definitions revisited

The Therapeutic Index quantifies safety: TI = TD₅₀ / ED₅₀. A high TI (e.g., penicillins) permits wide dosing windows; a low TI (e.g., aminoglycosides, vancomycin) mandates therapeutic drug monitoring. Post-antibiotic effect (PAE) is the persistent suppression of bacterial regrowth after brief antimicrobial exposure — prolonged for aminoglycosides (2–8 h) and fluoroquinolones, negligible for most β-lactams.

Mechanisms of action, mapped to targets

Cell-wall inhibitors: β-lactams bind penicillin-binding proteins (PBPs) and block transpeptidation; glycopeptides (vancomycin) bind d-Ala-d-Ala termini.
Protein synthesis inhibitors: macrolides and linezolid target the 50S subunit; tetracyclines, aminoglycosides target the 30S subunit.
Nucleic acid inhibitors: fluoroquinolones trap the DNA–enzyme complex; rifampicin blocks bacterial RNA polymerase.
Folate antagonists: sulfonamides are PABA analogues inhibiting dihydropteroate synthase; trimethoprim inhibits dihydrofolate reductase.
Membrane disruptors: daptomycin inserts into Gram-positive membranes (Ca²⁺-dependent); polymyxins bind LPS of Gram-negatives.

Resistance mechanisms

Mechanism	Example
Enzymatic inactivation	β-lactamases hydrolyzing penicillins; AMEs on aminoglycosides
Target modification	Altered PBP2a in MRSA; 23S rRNA methylation (erm genes) in macrolide resistance
Reduced permeability	Porin loss (OmpF/OmpC) in Enterobacter spp.
Efflux pumps	Tet(A–E), MexAB-OprM in Pseudomonas

Horizontal transfer via plasmids, transposons, and integrons spreads resistance faster than point mutation, especially in ICU and transplant wards.

Combination therapy logic

Synergism is achieved when 1+1 > 2 (e.g., β-lactam + aminoglycoside in enterococcal endocarditis; TMP-SMX sequential blockade of folate synthesis). Antagonism is rare but real — chloramphenicol plus a β-lactam blocks the active growth phase that β-lactams require. Combinations also prevent resistance (TB, HIV) and broaden empiric coverage (neutropenic fever).

Superinfection

Broad-spectrum therapy eradicates normal flora, opening niches for Clostridioides difficile, Candida spp., Pseudomonas aeruginosa, and MRSA. Diarrhea, pseudomembranous colitis, and oral/vaginal candidiasis are the classic INI CET vignettes.

Scoring tip: Read clinical stems for the word “after weeks of broad-spectrum antibiotics” — the question is almost always about C. difficile or candidal superinfection.

🔴 Extended — Deep Study (3mo+)

Comprehensive coverage for students on a longer study timeline.

PK/PD-driven dosing — why intervals differ

β-Lactams exhibit time-dependent killing with minimal PAE, so efficacy depends on the fraction of the dosing interval that free drug exceeds the MIC (%fT>MIC). Target ≥40–50% fT>MIC for penicillins and ≥60% for cephalosporins. Continuous or prolonged infusions exploit this. Aminoglycosides and fluoroquinolones are concentration-dependent: push the peak high (Cmax/MIC ≥ 8–10) and accept long intervals to allow the PAE to cover the trough.

Prophylactic chemotherapy — rules that examiners test

A prophylactic regimen should use one effective agent, the shortest effective duration, and appropriate timing. Surgical prophylaxis with cefazolin must begin within 60 minutes before incision; a second dose is justified only if the procedure exceeds two half-lives or there is major blood loss. Post-operative continuation beyond 24 hours is a common audit-rejected error.

Adjacent-topic hooks

Mechanism-of-action charts link Topic 9 with anti-tubercular drugs (Topic 10) and antimalarials.
Resistance genetics intersects with microbiology: ESBL, AmpC, carbapenemases (KPC, NDM, OXA-48) are repeat MCQ themes.
Adverse effects of specific antimicrobials — e.g., red-man syndrome (vancomycin infusion rate), ototoxicity/nephrotoxicity (aminoglycosides), tooth discoloration (tetracyclines in pregnancy/children) — frequently combine with this topic.

Common traps

β-Lactamase inhibitors (clavulanic acid, sulbactam, tazobactam) have weak intrinsic activity; they only restore the partner β-lactam’s activity.
TMP-SMX is bacteriostatic in most tissues but bactericidal in the urinary tract because urine concentrates the drug.
“Bacteriostatic drugs are inferior” is wrong in immunocompetent hosts; static and cidal agents produce equivalent cure rates in most non-endocarditis infections.

Practice prompts

A broth microdilution shows visible growth at 4 µg/mL, no growth at 8 µg/mL; subculture from the 8 µg/mL well yields no colonies. Define MIC, MBC, and interpret the ratio.
A neutropenic patient on imipenem develops new fever on day 7 with blood cultures growing C. difficile. Explain the mechanism and list two non-antibiotic risk factors that amplify it.

Continue your study

View this topic in your INI CET (AIIMS PG) roadmap — see where “Topic 9” fits in your personalised plan
Build a quick revision plan — 1-day sprint covering highest-weight topics
INI CET (AIIMS PG) exam overview — pattern, eligibility, and syllabus
All Pharmacology notes — browse sibling topics in this subject

Content adapted based on your selected roadmap duration. Switch tiers using the selector above.

Core definitions revisited